cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.29040043
title: Analyzing factors influencing hospitalization costs for five common cancers in China using neural network models

description: Malignant tumors are a major global health crisis, causing 25% of deaths in China, with lung, liver, thyroid, breast, and colon cancers being the most common. Understanding the factors influencing hospitalization costs for these cancers is crucial for public health and economics. This study aimed to identify key cost factors and develop a neural network model for predicting hospitalization costs, thereby providing tools to ease the financial burden on patients and healthcare systems. Data on hospitalization costs for 30,893 cancer patients from secondary or higher-level hospitals in Zhuhai, Guangdong Province, between 2017 and 2022, were analyzed. Neural network classification and feature importance analysis were used to determine the main factors influencing costs and to develop predictive models. Model performance was evaluated using the area under the receiver operating characteristic curve (AUROC), with a 95% confidence interval (CI) calculated for the AUROC value. The key factors influencing hospitalization costs for lung cancer are metastasis and malignant solid tumor (MST), with correlation coefficients of 0.126 and 0.086, respectively, both showing statistical significance (<i>p</i> &lt; 0.05). For colon cancer, the key factors influencing hospitalization costs are mortality and coronary disease (CD), with correlation coefficients of 0.092 and 0.090, respectively, both demonstrating statistical significance (<i>p</i> &lt; 0.05). The AUROC value for the lung cancer model is 0.9078 (95% CI = 0.8975–0.9186), and the AUROC value for the colon cancer model is 0.9017 (95% CI = 0.8848–0.9196). This study confirmed the strong clinical applicability of the neural network predictive model in analyzing hospitalization costs for lung and colon cancer and revealed the factors that influence hospitalization costs for these cancers.
DOI: 10.6084/m9.figshare.29040043.v1
title: Analyzing factors influencing hospitalization costs for five common cancers in China using neural network models

description: Malignant tumors are a major global health crisis, causing 25% of deaths in China, with lung, liver, thyroid, breast, and colon cancers being the most common. Understanding the factors influencing hospitalization costs for these cancers is crucial for public health and economics. This study aimed to identify key cost factors and develop a neural network model for predicting hospitalization costs, thereby providing tools to ease the financial burden on patients and healthcare systems. Data on hospitalization costs for 30,893 cancer patients from secondary or higher-level hospitals in Zhuhai, Guangdong Province, between 2017 and 2022, were analyzed. Neural network classification and feature importance analysis were used to determine the main factors influencing costs and to develop predictive models. Model performance was evaluated using the area under the receiver operating characteristic curve (AUROC), with a 95% confidence interval (CI) calculated for the AUROC value. The key factors influencing hospitalization costs for lung cancer are metastasis and malignant solid tumor (MST), with correlation coefficients of 0.126 and 0.086, respectively, both showing statistical significance (<i>p</i> &lt; 0.05). For colon cancer, the key factors influencing hospitalization costs are mortality and coronary disease (CD), with correlation coefficients of 0.092 and 0.090, respectively, both demonstrating statistical significance (<i>p</i> &lt; 0.05). The AUROC value for the lung cancer model is 0.9078 (95% CI = 0.8975–0.9186), and the AUROC value for the colon cancer model is 0.9017 (95% CI = 0.8848–0.9196). This study confirmed the strong clinical applicability of the neural network predictive model in analyzing hospitalization costs for lung and colon cancer and revealed the factors that influence hospitalization costs for these cancers.
DOI: 10.6084/m9.figshare.27931539
title: The burden of venous thromboembolism in ten countries: a cost-of-illness Markov model on surgical and ICU patients

description: The objective of this study was to assess the burden of hospital-acquired venous thromboembolism (VTE) on healthcare systems and patients across ten countries. A multi-methodological approach was taken to estimate the burden of hospital-acquired VTE across five key clinical specialties and ten countries (Australia, Brazil, China, France, Mexico, South Korea, Spain, Taiwan, Thailand, and the United Kingdom). Surveys with healthcare professionals (surgeons, hematologists, and hospital management) were conducted to identify clinical specialties of interest. A systematic literature review and interviews were conducted to identify data for incidences and costs. A health-economic model was developed, using a decision tree and Markov model to estimate 1-year costs. Costs are presented in 2022 USD. Orthopedics, oncology, long-term ICU, cardiology, and obstetrics and gynecology were identified as the clinical specialties of interest. The total cost burden of hospital-acquired VTE was estimated to be $41,280 million, which equals $503 per patient at risk. Expressed as a share of 2022 GDP, an average spending per country of 0.05% to 0.18% was observed. The VTE-associated mortality was substantial, accounting for 150,081 deaths in a 74.2 million population, translating into an average mortality rate of 2.02 (0.64–3.05) per 1,000 patients at risk. There were limited data available concerning VTE incidences in some countries and clinical specialties. Where data were available, there was heterogeneity of incidence definitions across the identified studies. Generalizations, imputations, and the country-agnostic structure of the model might have contributed to biases. The burden of hospital-acquired VTE is substantial both from an economic and from a patient perspective in all countries evaluated.
DOI: 10.6084/m9.figshare.27931539.v2
title: The burden of venous thromboembolism in ten countries: a cost-of-illness Markov model on surgical and ICU patients

description: The objective of this study was to assess the burden of hospital-acquired venous thromboembolism (VTE) on healthcare systems and patients across ten countries. A multi-methodological approach was taken to estimate the burden of hospital-acquired VTE across five key clinical specialties and ten countries (Australia, Brazil, China, France, Mexico, South Korea, Spain, Taiwan, Thailand, and the United Kingdom). Surveys with healthcare professionals (surgeons, hematologists, and hospital management) were conducted to identify clinical specialties of interest. A systematic literature review and interviews were conducted to identify data for incidences and costs. A health-economic model was developed, using a decision tree and Markov model to estimate 1-year costs. Costs are presented in 2022 USD. Orthopedics, oncology, long-term ICU, cardiology, and obstetrics and gynecology were identified as the clinical specialties of interest. The total cost burden of hospital-acquired VTE was estimated to be $41,280 million, which equals $503 per patient at risk. Expressed as a share of 2022 GDP, an average spending per country of 0.05% to 0.18% was observed. The VTE-associated mortality was substantial, accounting for 150,081 deaths in a 74.2 million population, translating into an average mortality rate of 2.02 (0.64–3.05) per 1,000 patients at risk. There were limited data available concerning VTE incidences in some countries and clinical specialties. Where data were available, there was heterogeneity of incidence definitions across the identified studies. Generalizations, imputations, and the country-agnostic structure of the model might have contributed to biases. The burden of hospital-acquired VTE is substantial both from an economic and from a patient perspective in all countries evaluated.
DOI: 10.6084/m9.figshare.27931539.v1
title: The burden of venous thromboembolism in ten countries: A cost-of-illness Markov model on surgical and ICU-patients

description: The objective of this study was to assess the burden of hospital-acquired venous thromboembolism (VTE) on healthcare systems and patients across ten countries. A multi-methodological approach was taken to estimate the burden of hospital-acquired VTE across five key clinical specialties and ten countries (Australia, Brazil, China, France, Mexico, South Korea, Spain, Taiwan, Thailand, and the United Kingdom). Surveys with healthcare professionals (surgeons, hematologists, and hospital management) were conducted to identify clinical specialties of interest. A systematic literature review and interviews were conducted to identify data for incidences and costs. A health-economic model was developed, using a decision tree and Markov model to estimate one-year costs. Costs are presented in 2022 USD. Orthopedics, oncology, long-term ICU, cardiology, and obstetrics and gynecology were identified as the clinical specialties of interest. The total cost burden of hospital-acquired VTE was estimated to be $41,280 million, which equals $503 per patient at risk. Expressed as a share of 2022 GDP, an average spending per country of 0.05% to 0.18% was observed. The VTE-associated mortality was substantial, accounting for 150,081 deaths in a 74.2 million population, translating into an average mortality rate of 2.02 (0.64-3.05) per 1,000 patients at risk. There were limited data available concerning VTE incidences in some countries and clinical specialties. Where data were available, there was heterogeneity of incidence definitions across the identified studies. Generalizations, imputations, and the country-agnostic structure of the model might have contributed to biases. The burden of hospital-acquired VTE is substantial both from an economic and from a patient perspective in all countries evaluated.
DOI: 10.6084/m9.figshare.28071636
title: Evaluating the cost-utility of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anaemia in Norway

description: Iron deficiency anemia (IDA) is among the most common extraintestinal sequelae of inflammatory bowel disease (IBD). Intravenous iron is often the preferred treatment in patients with active inflammation with or without active bleeding, iron malabsorption, or intolerance to oral iron. The aim of the present study was to evaluate the cost-utility of ferric derisomaltose (FDI) versus ferric carboyxymaltose (FCM) in patients with IBD and IDA in Norway. A published patient-level simulation model was used to evaluate the cost-utility of FDI versus FCM in patients with IBD and IDA from a Norwegian national payer perspective. Iron need was modelled based on bivariate distributions of hemoglobin and bodyweight combined with simplified tables of iron need from the FDI and FCM summaries of product characteristics. Patient characteristics and disease-related quality of life data were obtained from the PHOSPHARE-IBD trial. Cost-utility was evaluated in Norwegian Kroner (NOK) over a five-year time horizon. Patients required 1.64 fewer infusions of FDI than FCM over five years (5.62 versus 7.26), corresponding to 0.41 fewer infusions per treatment course. The reduction in the number of infusions resulted in cost savings of NOK 5,236 (NOK 35,830 with FDI versus NOK 41,066 with FCM). The need for phosphate testing in patients treated with FCM resulted in further cost savings with FDI (no costs with FDI versus NOK 4,470 with FCM). Total cost savings with FDI were therefore NOK 9,707. FDI also increased quality-adjusted life expectancy by 0.071 quality-adjusted life years (QALYs) driven by reduced incidence of hypophosphatemia and fewer interactions with the healthcare system. FDI resulted in cost savings and improved quality-adjusted life expectancy versus FCM in patients with IDA and IBD in Norway. FDI therefore represents the economically preferable iron formulation in Norwegian patients with IBD and IDA in whom it is indicated.
DOI: 10.6084/m9.figshare.28071636.v2
title: Evaluating the cost-utility of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anaemia in Norway

description: Iron deficiency anemia (IDA) is among the most common extraintestinal sequelae of inflammatory bowel disease (IBD). Intravenous iron is often the preferred treatment in patients with active inflammation with or without active bleeding, iron malabsorption, or intolerance to oral iron. The aim of the present study was to evaluate the cost-utility of ferric derisomaltose (FDI) versus ferric carboyxymaltose (FCM) in patients with IBD and IDA in Norway. A published patient-level simulation model was used to evaluate the cost-utility of FDI versus FCM in patients with IBD and IDA from a Norwegian national payer perspective. Iron need was modelled based on bivariate distributions of hemoglobin and bodyweight combined with simplified tables of iron need from the FDI and FCM summaries of product characteristics. Patient characteristics and disease-related quality of life data were obtained from the PHOSPHARE-IBD trial. Cost-utility was evaluated in Norwegian Kroner (NOK) over a five-year time horizon. Patients required 1.64 fewer infusions of FDI than FCM over five years (5.62 versus 7.26), corresponding to 0.41 fewer infusions per treatment course. The reduction in the number of infusions resulted in cost savings of NOK 5,236 (NOK 35,830 with FDI versus NOK 41,066 with FCM). The need for phosphate testing in patients treated with FCM resulted in further cost savings with FDI (no costs with FDI versus NOK 4,470 with FCM). Total cost savings with FDI were therefore NOK 9,707. FDI also increased quality-adjusted life expectancy by 0.071 quality-adjusted life years (QALYs) driven by reduced incidence of hypophosphatemia and fewer interactions with the healthcare system. FDI resulted in cost savings and improved quality-adjusted life expectancy versus FCM in patients with IDA and IBD in Norway. FDI therefore represents the economically preferable iron formulation in Norwegian patients with IBD and IDA in whom it is indicated.
DOI: 10.6084/m9.figshare.30050401
title: A retrospective cohort study of the economic burden of Pompe disease in patients treated with enzyme replacement therapy in the United States

description: To describe the economic burden of Pompe disease in patients treated with enzyme replacement therapy (ERT) in the US. A retrospective cohort study (1 January 2012–30 September 2022) was conducted using the Merative™ MarketScan Research Databases. Patients with ≥2 outpatient or ≥1 inpatient claims of Pompe disease, ≥1 claim of ERT, and continuous enrollment in medical/prescription coverage for ≥90 days prior to the diagnosis date for patients ≥2 years and ≥1-month post-index were included. Patients were stratified into infantile-onset Pompe disease (IOPD) or late-onset Pompe disease (LOPD) cohorts using age at diagnosis and clinical presentation. Healthcare resource utilization and costs were evaluated over the follow-up period. A total of 105 patients were included (IOPD: <i>n</i> = 50; LOPD: <i>n</i> = 55 [mean age at diagnosis: IOPD: 0.3 years, LOPD: 32.2 years; male: IOPD: 66%, LOPD: 60%]). Mean follow-up length was 914 and 987 days in the IOPD and LOPD cohorts, respectively. Forty-seven (94.0%) patients with IOPD and 49 (89.1%) with LOPD utilized ≥1 all-cause outpatient service, while 23 (46.0%) and 16 (29.0%), respectively, had ≥1 all-cause hospitalization. Mean total all-cause costs were $950,380 in patients with IOPD and $185,7823 in those with LOPD. Mean all-cause outpatient costs were $559,888 and $122,2078, while mean all-cause inpatient costs were $169,781 and $60,584 in the IOPD and LOPD cohorts, respectively. The all-cause outpatient ERT cost was $308,421 in patients with IOPD and $778,190 in those with LOPD. Pompe disease incurs a substantial economic burden in patients despite treatment with ERT. For both types of Pompe disease, the primary drivers of costs were outpatient- and ERT-related; however, patients with IOPD had higher inpatient and supportive care utilization and costs, whereas patients with LOPD had higher costs for outpatient services.
DOI: 10.6084/m9.figshare.30050401.v1
title: A retrospective cohort study of the economic burden of Pompe disease in patients treated with enzyme replacement therapy in the United States

description: To describe the economic burden of Pompe disease in patients treated with enzyme replacement therapy (ERT) in the US. A retrospective cohort study (1 January 2012–30 September 2022) was conducted using the Merative™ MarketScan Research Databases. Patients with ≥2 outpatient or ≥1 inpatient claims of Pompe disease, ≥1 claim of ERT, and continuous enrollment in medical/prescription coverage for ≥90 days prior to the diagnosis date for patients ≥2 years and ≥1-month post-index were included. Patients were stratified into infantile-onset Pompe disease (IOPD) or late-onset Pompe disease (LOPD) cohorts using age at diagnosis and clinical presentation. Healthcare resource utilization and costs were evaluated over the follow-up period. A total of 105 patients were included (IOPD: <i>n</i> = 50; LOPD: <i>n</i> = 55 [mean age at diagnosis: IOPD: 0.3 years, LOPD: 32.2 years; male: IOPD: 66%, LOPD: 60%]). Mean follow-up length was 914 and 987 days in the IOPD and LOPD cohorts, respectively. Forty-seven (94.0%) patients with IOPD and 49 (89.1%) with LOPD utilized ≥1 all-cause outpatient service, while 23 (46.0%) and 16 (29.0%), respectively, had ≥1 all-cause hospitalization. Mean total all-cause costs were $950,380 in patients with IOPD and $185,7823 in those with LOPD. Mean all-cause outpatient costs were $559,888 and $122,2078, while mean all-cause inpatient costs were $169,781 and $60,584 in the IOPD and LOPD cohorts, respectively. The all-cause outpatient ERT cost was $308,421 in patients with IOPD and $778,190 in those with LOPD. Pompe disease incurs a substantial economic burden in patients despite treatment with ERT. For both types of Pompe disease, the primary drivers of costs were outpatient- and ERT-related; however, patients with IOPD had higher inpatient and supportive care utilization and costs, whereas patients with LOPD had higher costs for outpatient services.
DOI: 10.6084/m9.figshare.28920753
title: The patient journey and burden of disease in <i>Demodex</i> blepharitis in the United States

description: <i>Demodex</i> blepharitis (DB) is a chronic eyelid disease caused by an infestation of <i>Demodex</i> mites. The objective of this chart audit study was to characterize the patient journey and burden of illness associated with DB from an eye-care provider’s perspective. Retrospective medical data for patients with a confirmed diagnosis of DB were anonymously collected <i>via</i> ophthalmologists and optometrists in the US (collectively eye-care providers [ECPs]), in June-July 2022. Each eligible ECP completed a questionnaire and provided chart abstractions of 1–5 medical charts of patients with DB in an electronic case report form. All ECPs (<i>N</i> = 61) were ophthalmologists or optometrists who worked primarily in office-based private practices (97%). Data from 192 medical charts of patients with an ECP-confirmed diagnosis of DB were abstracted and their demographics included 54% males and 71% Caucasians. The mean time (±SD) since diagnosis was 11 (±9.0) years. Over 40% of patients were not examined for DB at initial presentation, and the average time from initial presentation to a definitive diagnosis for DB was 6.5 months. After DB diagnosis and across the period of observation until the time of the study, patients had a mean (±SD) of 3.2 (±2.8) follow-up visits due to DB and continued to use multiple off-label prescription and over-the-counter therapies for symptom management. Medical records may be incomplete or inconsistently reported and subject to recall bias. The patient journey is lengthy with multiple challenges, including delay in DB diagnosis and recurring DB symptoms, underlining an urgent need for action to improve diagnosis and treatment of DB. <i>Demodex</i> blepharitis, caused by <i>Demodex</i> mite infestation, is a prevalent chronic disease of the eyelid. This study examined the patient experiences and the burden of the disease from the eye-care providers’ perspectives. Many patients experienced delays in diagnosis, with over 40% were not examined for <i>Demodex</i> blepharitis initially. On average, diagnosis took 6.5 months from the initial presentation. Patients required multiple follow-up visits (average 3.2) and used various management therapies after diagnosis. The results underscore the impact of <i>Demodex</i> blepharitis and emphasize the importance of early detection and improved treatment strategies to better patient experiences and outcomes.
DOI: 10.6084/m9.figshare.28920753.v2
title: The patient journey and burden of disease in <i>Demodex</i> blepharitis in the United States

description: <i>Demodex</i> blepharitis (DB) is a chronic eyelid disease caused by an infestation of <i>Demodex</i> mites. The objective of this chart audit study was to characterize the patient journey and burden of illness associated with DB from an eye-care provider’s perspective. Retrospective medical data for patients with a confirmed diagnosis of DB were anonymously collected <i>via</i> ophthalmologists and optometrists in the US (collectively eye-care providers [ECPs]), in June-July 2022. Each eligible ECP completed a questionnaire and provided chart abstractions of 1–5 medical charts of patients with DB in an electronic case report form. All ECPs (<i>N</i> = 61) were ophthalmologists or optometrists who worked primarily in office-based private practices (97%). Data from 192 medical charts of patients with an ECP-confirmed diagnosis of DB were abstracted and their demographics included 54% males and 71% Caucasians. The mean time (±SD) since diagnosis was 11 (±9.0) years. Over 40% of patients were not examined for DB at initial presentation, and the average time from initial presentation to a definitive diagnosis for DB was 6.5 months. After DB diagnosis and across the period of observation until the time of the study, patients had a mean (±SD) of 3.2 (±2.8) follow-up visits due to DB and continued to use multiple off-label prescription and over-the-counter therapies for symptom management. Medical records may be incomplete or inconsistently reported and subject to recall bias. The patient journey is lengthy with multiple challenges, including delay in DB diagnosis and recurring DB symptoms, underlining an urgent need for action to improve diagnosis and treatment of DB. <i>Demodex</i> blepharitis, caused by <i>Demodex</i> mite infestation, is a prevalent chronic disease of the eyelid. This study examined the patient experiences and the burden of the disease from the eye-care providers’ perspectives. Many patients experienced delays in diagnosis, with over 40% were not examined for <i>Demodex</i> blepharitis initially. On average, diagnosis took 6.5 months from the initial presentation. Patients required multiple follow-up visits (average 3.2) and used various management therapies after diagnosis. The results underscore the impact of <i>Demodex</i> blepharitis and emphasize the importance of early detection and improved treatment strategies to better patient experiences and outcomes.